** Shares of Unity Biotechnology UBX.O fall 35.3% to $1.18

** Drug developer says its treatment for a type of eye disease failed to meet the main goal of a mid-stage trial

** Co was testing the treatment in patients with diabetic macular edema $(DME.AU)$, an eye condition that causes swelling in the retina in those who have poor vision despite prior treatment

** Co says the treatment, UBX1325, did not meet the main goal of statistical non-inferiority to Regeneron's REGN.O Eylea, the standard of care treatment for patients with DME

** Co, however, says UBX1325 showed improvements in clarity of vision of over 5 letters at weeks 24 and 36

** Co anticipates the complete results from the remaining patients in Q2 of 2025

** Stock had fallen 49.4% in 2024

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))